← Eichor
Study identifier: NCT07583511 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study

Condition: Small-cell Lung Cancer  ·  Sponsor: Sun Yat-sen University

PhasePhase 2
Planned participants90
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

To compare the efficacy and safety between teniposide, cisplatin and serplulimab regimen and etoposide, cisplatin and serplulimab regimen in the treatment of extensive stage small lung cancer

This description comes directly from the study's public registry record.

Talk to the study team

Wenfeng Fang  ·  15322302066  ·  48287672@qq.com

Always discuss trial participation with your own doctor first.

Locations (1)

SUN-YAT-SEN University Cancer CenterGuangzhou, Guangdong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07583511